Evaluation of Viral Status of Patients With Plantar Warts Included in VRAIE Study, Non-responder to Study Treatment (BIOVRAIE)

Centre Hospitalier Universitaire de Besancon

Status: Terminated

Conditions: Plantar Warts

Treatments: Genetic: skin flakes collection

Study type: Observational

Funder types: Other

Identifiers

NCT02861404

BIOVRAIE

Details and patient eligibility

About

The principal objective of the study is the evaluation of the role of Human Papilloma Virus (HPV) in plantar warts (prevalence, genotype), resistant or not, treated or not, cured or not. This epidemiological study is an ancillary study of the prospective, randomized controlled, clinical study VRAIE (sponsor: APHP) comparing 5 usual strategies in the management of plantar warts.

Enrollment: 406 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female patient aged 18 years or more.

• Clinical evaluation

• Number of warts lower than 10 on the 2 feet and total diameter of warts lower than 10 cm, whether previously treated or not

• In treated patients, all potentially active treatment on warts since at least one month should be stopped.

• Effective contraception for women of childbearing age

• Immunocompetent patients

• Patient with one or more warts on soles and board feet.

  • MYRMECIE : rounded warts, deep, covered with a stratum corneum more or less thick; after stripping, appear black points, very specific; often painful to pressure. They are lonely, single or not. They could regroup galley thick. The stripping can them to individualize.
  • Mosaic : plate small warts, superficial, often sitting on the heel or Forefoot. Little painful, they are often ignored by the patients when they appear

• Patient affiliated to the French social security.viral

Exclusion criteria

• Patient suspected to be immunocompromised
• Patient aged under 18 years
• Patient refusing to sign the consent
• Pregnant or lactating women
• Plantar calluses
• Known hypersensitivity to imiquimod (Aldara®) or any excipients of the cream (isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, paraffin, polysorbate 60, sorbitan stearate, glycerol, methyl hydroxybenzoate, propyl hydroxybenzoate, xanthan gum, purified water)
• Known hypersensitivity to 5 fluoro-uracil (Efudix®) or any excipients of gel (stearyl alcohol, Vaseline, polysorbate 60, propyleneglycol, purified water - conservatives: METHYL PARAHYDROXYBENZOATE, PROPYL PARAHYDROXYBENZOATE)
• Contra-indication to Pomade M.O Cochon® (Known allergy to any components)
• Known hypersensitivity to Blenderm®
• Extra plantar concomitant warts (to exclude risk of endogenous recontamination by an extra plantar site)
• Plantar hyperhidrosis making impossible adhesion of plaster.

Trial design

406 participants in 5 patient groups

Salicylate ointment

Description:

patients included in VRAIE study, treated with salicylate ointment (VRAIE study, NCT01059110)

Treatment:

Genetic: skin flakes collection

Imiquimod

Description:

patients included in VRAIE study, treated with Imiquimod (VRAIE study, NCT01059110)

Treatment:

Genetic: skin flakes collection

5-Fluoro-Uracil

Description:

patients included in VRAIE study, treated with 5-Fluoro-Uracil (VRAIE study, NCT01059110)

Treatment:

Genetic: skin flakes collection

Cryotherapy

Description:

patients included in VRAIE study, treated with cryotherapy (VRAIE study, NCT01059110)

Treatment:

Genetic: skin flakes collection

placebo

Description:

patients included in VRAIE study, receiving placebo (VRAIE study, NCT01059110)

Treatment:

Genetic: skin flakes collection